AUGMEDIX INC (AUGX) Stock Price, Quote, News and Overview
NASDAQ:AUGX - Nasdaq - US05105P1075 - Common Stock - Currency: USD
AUGX Quote, Performance and Key Statistics
2.35
0 (0%)
The current stock price of AUGX is 2.35 USD. In the past month the price increased by 1.73%. In the past year, price decreased by -53.47%.
AUGX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 36.13 | 36.66B | ||
| DOCS | DOXIMITY INC-CLASS A | 56.54 | 13.58B | ||
| WAY | WAYSTAR HOLDING CORP | N/A | 7.26B | ||
| CERT | CERTARA INC | 33.77 | 2.12B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.98B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 15.03 | 1.83B | ||
| SDGR | SCHRODINGER INC | N/A | 1.65B | ||
| PHR | PHREESIA INC | N/A | 1.64B | ||
| EVH | EVOLENT HEALTH INC - A | 15.8 | 1.22B | ||
| HSTM | HEALTHSTREAM INC | 50.58 | 999.88M | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 966.46M | ||
| DH | DEFINITIVE HEALTHCARE CORP | 14.47 | 762.50M |
Related stock screener links
About AUGX
Company Profile
Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. The company is headquartered in San Francisco, California and currently employs 1,430 full-time employees. The company went IPO on 2021-03-04. The firm uses its proprietary Notebuilder Platform to automate the note creation process, aided by its trained MDSs. The company also provides data services associated with these products, which include aggregated structured data and metadata associated with medical notes. Its products include Augmedix Live, Augmedix Notes, Augmedix Prep and Augmedix Go. Augmedix Live provides synchronous medical note documentation and point of care support. Augmedix Notes provides asynchronous medical documentation based upon previously recorded visit. Prep provides chart preparation delivered prior to the patient visit. Prep transfers patient demographics, past medical history, medication changes and other key data points from the patient’s health to the current visit note. Clinicians access its products and service through mobile devices, managed by it or their health enterprise.
Company Info
AUGMEDIX INC
111 Sutter Street, Suite 1300
San Francisco CALIFORNIA US
CEO: Emmanuel Krakaris
Employees: 1430
Company Website: https://augmedix.com/
Phone: 15619892208
AUGMEDIX INC / AUGX FAQ
What is the stock price of AUGMEDIX INC today?
The current stock price of AUGX is 2.35 USD.
What is the ticker symbol for AUGMEDIX INC stock?
The exchange symbol of AUGMEDIX INC is AUGX and it is listed on the Nasdaq exchange.
On which exchange is AUGX stock listed?
AUGX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AUGMEDIX INC stock?
10 analysts have analysed AUGX and the average price target is 3.6 USD. This implies a price increase of 53% is expected in the next year compared to the current price of 2.35. Check the AUGMEDIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AUGMEDIX INC worth?
AUGMEDIX INC (AUGX) has a market capitalization of 116.16M USD. This makes AUGX a Micro Cap stock.
How many employees does AUGMEDIX INC have?
AUGMEDIX INC (AUGX) currently has 1430 employees.
What are the support and resistance levels for AUGMEDIX INC (AUGX) stock?
AUGMEDIX INC (AUGX) has a support level at 2.34 and a resistance level at 2.36. Check the full technical report for a detailed analysis of AUGX support and resistance levels.
Is AUGMEDIX INC (AUGX) expected to grow?
The Revenue of AUGMEDIX INC (AUGX) is expected to grow by 18.97% in the next year. Check the estimates tab for more information on the AUGX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AUGMEDIX INC (AUGX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AUGX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AUGX, evaluating the profitability, health, valuation and growth aspects
- AUGMEDIX INC (AUGX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AUGMEDIX INC (AUGX) Sales and EPS estimates to see what analysts future expectations are.
- AUGMEDIX INC (AUGX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AUGMEDIX INC (AUGX) Insider and Institutional Ownership to learn about the owners and their transactions.
- AUGMEDIX INC (AUGX) Stock Chart to make your own analysis
- AUGMEDIX INC (AUGX) Latest news and press-releases to stay up to date.
Does AUGMEDIX INC (AUGX) stock pay dividends?
AUGX does not pay a dividend.
When does AUGMEDIX INC (AUGX) report earnings?
AUGMEDIX INC (AUGX) will report earnings on 2024-11-04, before the market open.
What is the Price/Earnings (PE) ratio of AUGMEDIX INC (AUGX)?
AUGMEDIX INC (AUGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.44).
AUGX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AUGX. When comparing the yearly performance of all stocks, AUGX is one of the better performing stocks in the market, outperforming 90.44% of all stocks.
AUGX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AUGX. AUGX may be in some trouble as it scores bad on both profitability and health.
AUGX Financial Highlights
Over the last trailing twelve months AUGX reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 15.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.44% | ||
| ROE | -227.72% | ||
| Debt/Equity | 1.48 |
AUGX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to AUGX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -20.13% and a revenue growth 18.97% for AUGX